GSK
Price
$38.96
Change
-$0.71 (-1.79%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
79.39B
57 days until earnings call
PFE
Price
$24.98
Change
+$0.22 (+0.89%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
140.77B
63 days until earnings call
Interact to see
Advertisement

GSK vs PFE

Header iconGSK vs PFE Comparison
Open Charts GSK vs PFEBanner chart's image
GSK
Price$38.96
Change-$0.71 (-1.79%)
Volume$30.94K
Capitalization79.39B
Pfizer
Price$24.98
Change+$0.22 (+0.89%)
Volume$322.23K
Capitalization140.77B
GSK vs PFE Comparison Chart in %
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GSK vs. PFE commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and PFE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (GSK: $39.67 vs. PFE: $24.76)
Brand notoriety: GSK: Not notable vs. PFE: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 76% vs. PFE: 90%
Market capitalization -- GSK: $79.39B vs. PFE: $140.77B
GSK [@Pharmaceuticals: Major] is valued at $79.39B. PFE’s [@Pharmaceuticals: Major] market capitalization is $140.77B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.73B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • GSK’s FA Score: 2 green, 3 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, GSK is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 7 bullish TA indicator(s).

  • GSK’s TA Score: 6 bullish, 4 bearish.
  • PFE’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, PFE is a better buy in the short-term than GSK.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а -1.29% price change this week, while PFE (@Pharmaceuticals: Major) price change was -4.33% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.29%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was +10.10%.

Reported Earning Dates

GSK is expected to report earnings on Oct 29, 2025.

PFE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.29% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($141B) has a higher market cap than GSK($79.4B). GSK has higher P/E ratio than PFE: GSK (17.75) vs PFE (13.10). GSK YTD gains are higher at: 21.276 vs. PFE (-1.651). PFE has higher annual earnings (EBITDA): 20.2B vs. GSK (8.61B). PFE has more cash in the bank: 13.2B vs. GSK (3.62B). GSK has less debt than PFE: GSK (17.4B) vs PFE (60.9B). PFE has higher revenues than GSK: PFE (63.8B) vs GSK (31.6B).
GSKPFEGSK / PFE
Capitalization79.4B141B56%
EBITDA8.61B20.2B43%
Gain YTD21.276-1.651-1,289%
P/E Ratio17.7513.10136%
Revenue31.6B63.8B50%
Total Cash3.62B13.2B27%
Total Debt17.4B60.9B29%
FUNDAMENTALS RATINGS
GSK vs PFE: Fundamental Ratings
GSK
PFE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
4062
PRICE GROWTH RATING
1..100
5655
P/E GROWTH RATING
1..100
2797
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as GSK (6). This means that PFE’s stock grew similarly to GSK’s over the last 12 months.

GSK's Profit vs Risk Rating (65) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that GSK’s stock grew somewhat faster than PFE’s over the last 12 months.

GSK's SMR Rating (40) in the Pharmaceuticals Major industry is in the same range as PFE (62). This means that GSK’s stock grew similarly to PFE’s over the last 12 months.

PFE's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as GSK (56). This means that PFE’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (27) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (97). This means that GSK’s stock grew significantly faster than PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKPFE
RSI
ODDS (%)
Bearish Trend 5 days ago
46%
Bearish Trend 5 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
46%
Bullish Trend 5 days ago
51%
Momentum
ODDS (%)
Bullish Trend 5 days ago
46%
Bearish Trend 5 days ago
60%
MACD
ODDS (%)
Bullish Trend 5 days ago
48%
Bearish Trend 5 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
52%
Bearish Trend 5 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
53%
Bullish Trend 5 days ago
54%
Advances
ODDS (%)
Bullish Trend 7 days ago
58%
Bullish Trend 12 days ago
57%
Declines
ODDS (%)
Bearish Trend 28 days ago
54%
Bearish Trend 8 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
53%
Bullish Trend 5 days ago
60%
Aroon
ODDS (%)
Bullish Trend 5 days ago
45%
Bullish Trend 5 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
NKN.X0.025607-0.000430
-1.65%
NKN cryptocurrency
ONG.X0.161652-0.004736
-2.85%
Ontology Gas cryptocurrency
JUP.X0.474818-0.015053
-3.07%
Jupiter cryptocurrency
NBS.X0.000036-0.000002
-4.15%
New BitShares cryptocurrency
SKL.X0.029725-0.001519
-4.86%
SKALE cryptocurrency

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with AZN. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+0.58%
AZN - GSK
62%
Loosely correlated
-0.11%
PFE - GSK
56%
Loosely correlated
+0.65%
SNY - GSK
53%
Loosely correlated
-0.92%
JNJ - GSK
49%
Loosely correlated
+0.98%
BIIB - GSK
46%
Loosely correlated
-0.32%
More

PFE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PFE has been loosely correlated with MRK. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then MRK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PFE
1D Price
Change %
PFE100%
+0.65%
MRK - PFE
58%
Loosely correlated
+1.09%
NVS - PFE
57%
Loosely correlated
+0.06%
GSK - PFE
56%
Loosely correlated
+0.58%
BIIB - PFE
54%
Loosely correlated
-0.32%
BMY - PFE
51%
Loosely correlated
+0.64%
More